Kogenate treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy, and inhibitor development after seven study years.

被引：0
|
作者：
Lusher, J
Arkin, S
Abildgaard, CF
Hurst, D
机构：
[1] MT SINAI SCH MED,NEW YORK,NY
[2] WAYNE STATE UNIV,DETROIT,MI
[3] BAYER CORP,BERKELEY,CA
[4] UNIV CALIF DAVIS,SACRAMENTO,CA 95817
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1755 / 1755
页数：1
相关论文
共 50 条
  • [1] Recombinant FVII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy and inhibitor development after seven study years
    Lusher, J
    Arkin, S
    Abildgaard, CF
    Hurst, A
    THROMBOSIS AND HAEMOSTASIS, 1997, : PD664 - PD664
  • [2] KOGENATE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY, AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
    LUSHER, J
    ARKIN, S
    ABILDGAARD, CF
    HURST, D
    BLOOD, 1994, 84 (10) : A239 - A239
  • [3] RECOMBINANT FVIII (KOGENATE) TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
    LUSHER, JM
    ARKIN, S
    ABILDGAARD, CF
    HURST, D
    PEDIATRIC RESEARCH, 1995, 37 (04) : A161 - A161
  • [4] RECOMBINANT-FVIII (KOGENATE) TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY, AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
    LUSHER, J
    ARKIN, S
    ABILDGAARD, CF
    HURST, D
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1012 - 1012
  • [5] Safety and efficacy of KOGENATE® Bayer in previously untreated patients (PUPS) and minimally treated patients (MTPs)
    Giangrande, PLF
    HAEMOPHILIA, 2002, 8 : 19 - 22
  • [6] INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA RECEIVING KOGENATE - 4.5 YEAR FOLLOW-UP DATA, INCLUDING RESPONSE TO IMMUNE TOLERANCE (IT) WITH KOGENATE
    LUSHER, J
    ARKIN, S
    ABILDGAARD, C
    INWOOD, M
    HILGARTNER, M
    HURST, D
    PEDIATRIC RESEARCH, 1994, 35 (04) : A165 - A165
  • [7] Anti-FVIII inhibitor incidence in previously untreated patients (PUPs) with hemophilia exposed to Kogenate® (GIPSI-German-Italian PUP study on inhibitor)
    Gringeri, A
    Kreuz, W
    Escuriola-Ettinghausen, C
    Santagostino, E
    Saguer, IM
    Bader, R
    Budde, U
    Mannucci, PM
    THROMBOSIS RESEARCH, 1998, 91 (03) : S8 - S9
  • [8] US Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics
    Carpenter, Shannon L.
    Chandler, Martin
    Guerrera, Michael F.
    Malec, Lynn
    Manuel, Matthew
    Recht, Michael
    Reiss, Ulrike
    Sidonio, Robert F., Jr.
    Tarango, Cristina
    Van den Berg, Marijke
    Wang, Michael
    Thornburg, Courtney D.
    BLOOD, 2022, 140
  • [9] Validation of the prediction score for inhibitor development in previously untreated patients (PUPs) with severe hemophilia A
    Hashemi, S.
    Fischer, K.
    Van den Berg, H.
    HAEMOPHILIA, 2012, 18 : 89 - 89
  • [10] Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
    Taki, Masashi
    Fukutake, Katsuyuki
    Matsushita, Tadashi
    Nogami, Keiji
    Shima, Midori
    Yoshioka, Akira
    Takamatsu, Junki
    Arai, Morio
    Takagi, Hiroshi
    Uchikawa, Haruhiko
    Engl, Werner
    Shirahata, Akira
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 70 - 78
12345